Goldman Sachs Group, Inc. (The) cut shares of Evolent Health, Inc (NYSE:EVH) from a conviction-buy rating to a buy rating in a report released on Tuesday, The Fly reports.

A number of other research analysts have also recently commented on EVH. Robert W. Baird set a $35.00 price target on Evolent Health and gave the stock a buy rating in a research note on Tuesday, August 8th. SunTrust Banks, Inc. reaffirmed a buy rating and set a $30.00 price objective on shares of Evolent Health in a research report on Friday, November 3rd. Zacks Investment Research lowered Evolent Health from a hold rating to a sell rating in a research report on Thursday, August 10th. Cowen and Company reaffirmed an outperform rating and set a $33.00 price objective (down previously from $35.00) on shares of Evolent Health in a research report on Wednesday, August 9th. Finally, BidaskClub lowered Evolent Health from a buy rating to a hold rating in a research report on Monday, July 31st. Two analysts have rated the stock with a sell rating, one has given a hold rating and thirteen have given a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $28.70.

Evolent Health (EVH) traded down $0.55 on Tuesday, reaching $11.15. The company had a trading volume of 3,966,800 shares, compared to its average volume of 1,214,106. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.89 and a current ratio of 1.89. Evolent Health has a 12-month low of $10.35 and a 12-month high of $27.50.

Evolent Health (NYSE:EVH) last released its quarterly earnings results on Thursday, November 2nd. The technology company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.04. Evolent Health had a negative return on equity of 5.27% and a negative net margin of 15.86%. The company had revenue of $107.90 million for the quarter, compared to analysts’ expectations of $104.49 million. During the same period in the prior year, the firm earned ($0.26) earnings per share. The firm’s revenue was up 79.2% compared to the same quarter last year. analysts anticipate that Evolent Health will post -0.57 EPS for the current year.

TRADEMARK VIOLATION WARNING: This report was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.watchlistnews.com/evolent-health-inc-evh-lowered-to-buy-at-goldman-sachs-group-inc-the/1696196.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. FMR LLC boosted its stake in Evolent Health by 117.7% in the second quarter. FMR LLC now owns 9,864,775 shares of the technology company’s stock valued at $250,073,000 after acquiring an additional 5,333,252 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Evolent Health by 37.3% during the third quarter. JPMorgan Chase & Co. now owns 7,465,019 shares of the technology company’s stock worth $136,236,000 after buying an additional 2,026,893 shares during the period. Vanguard Group Inc. boosted its stake in shares of Evolent Health by 48.9% during the second quarter. Vanguard Group Inc. now owns 3,769,869 shares of the technology company’s stock worth $95,566,000 after buying an additional 1,237,941 shares during the period. Riverbridge Partners LLC acquired a new stake in shares of Evolent Health during the second quarter worth about $58,878,000. Finally, Blair William & Co. IL boosted its stake in shares of Evolent Health by 31.4% during the second quarter. Blair William & Co. IL now owns 2,185,695 shares of the technology company’s stock worth $55,407,000 after buying an additional 522,874 shares during the period. Institutional investors own 91.58% of the company’s stock.

Evolent Health Company Profile

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

The Fly

Analyst Recommendations for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.